Filter Results:
(1,300)
Show Results For
- All HBS Web
(1,300)
- People (4)
- News (227)
- Research (904)
- Events (4)
- Multimedia (7)
- Faculty Publications (496)
Show Results For
- All HBS Web
(1,300)
- People (4)
- News (227)
- Research (904)
- Events (4)
- Multimedia (7)
- Faculty Publications (496)
- August 1990 (Revised January 1992)
- Case
Eli Lilly and Co. (B): Europe
Examines the challenges facing the company in light of the changing economic, regulatory, and competitive environment in the European pharmaceutical industry. Examines the steps taken by the company adapting to this changing situation as part of a total globalization... View Details
Keywords: Change Management; Economics; Global Strategy; Business or Company Management; Growth and Development Strategy; Adaptation; Competition; Pharmaceutical Industry; Europe
Yoshino, Michael Y. "Eli Lilly and Co. (B): Europe." Harvard Business School Case 391-033, August 1990. (Revised January 1992.)
- March 1994 (Revised March 1995)
- Case
Astra/Merck Group
By: Frank V. Cespedes and Marie Bell
Astra/Merck (A/M), originally a joint venture of AB Astra and Merck & Co., is preparing to be an independent company in 1993. Since the company does not engage in basic research and development of drugs, it is essentially a distribution organization. Fundamental to... View Details
Keywords: Cost vs Benefits; Marketing Strategy; Distribution; Performance Evaluation; Research and Development; Risk and Uncertainty; Sales; Competitive Strategy; Pharmaceutical Industry
Cespedes, Frank V., and Marie Bell. "Astra/Merck Group." Harvard Business School Case 594-045, March 1994. (Revised March 1995.)
- Video
Said Darwazah
Said Darwazah, Executive Chairman and CEO of Hikma Pharmaceuticals PLC, argues that transitioning to a publicly held company ensures the continuity of a previously family-owned business. View Details
- 14 Jul 2021
- Blog Post
From Colombia to the District of Columbia: Making an Impact with Paulina Llano (MBA 2022)
herself in Boston at Harvard Business School and is spending the summer interning for a Cambridge-based pharmaceutical and biotech company that has become a household name – Moderna. The contributions Llano... View Details
Keywords: Health Care
- 09 Nov 2011
- News
Resistance Is Futile
- 22 Sep 2015
- News
Should Bank of America's CEO also be the chairman?
- 11 Oct 2010
- Research & Ideas
It Pays to Hire Women in Countries That Won’t
Call it corporate alchemy. New research finds that multinational companies can spin gender bias into gold by recruiting and hiring well-educated female managers in countries that traditionally discriminate... View Details
Keywords: by Carmen Nobel
- September 2014 (Revised February 2015)
- Case
Pfizer and AstraZeneca: Marketing an Acquisition (A)
By: John A. Quelch and James Weber
In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to... View Details
Keywords: Health Care Policy; Mergers And Acquisitions; Marketing; Government Relations; Crisis Management; Decision Making; Growth and Development; Management; Markets; Strategy; Pharmaceutical Industry; United Kingdom; United States
Quelch, John A., and James Weber. "Pfizer and AstraZeneca: Marketing an Acquisition (A)." Harvard Business School Case 515-007, September 2014. (Revised February 2015.)
- February 2015 (Revised November 2015)
- Supplement
Building an Integrated Biopharma Company: Crucell (B)
By: Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling
The Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8... View Details
Keywords: Biotechnology; Biopharmacy Company; Licensing Agreements In Biopharmacy; Licensing; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Entrepreneurship; Health Care and Treatment; Acquisition; Innovation and Invention; Pharmaceutical Industry; Pharmaceutical Industry
Hamermesh, Richard G., Marianne Van Der Steen, and Susan Harmeling. "Building an Integrated Biopharma Company: Crucell (B)." Harvard Business School Supplement 815-086, February 2015. (Revised November 2015.)
- Video
Dr. Silvia Gold
Dr. Silvia Gold, President of the Mundo Sano Foundation and co-founder of Grupo Insud, explains how patent expiration is important for innovation, recounting that her company has always won against large Western pharmaceutical companies that have sought legal action... View Details
- 01 Oct 2011
- News
Resistance Is Futile
- December 2007 (Revised May 2009)
- Case
Can PACIV (Puerto Rico) Serve European Customers?
Jorge Rodriguez-Gonzalez, PACIV's (Puerto Rico) founding CEO, is considering expanding PACIV's pharmaceutical manufacturing compliance services company to the U.K. and Europe. He has to decide whether to hire Wayne Snelgrove and how to define the scope of his... View Details
Keywords: Customer Focus and Relationships; Entrepreneurship; Cross-Cultural and Cross-Border Issues; Global Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Europe; United Kingdom; Puerto Rico
Isenberg, Daniel J. "Can PACIV (Puerto Rico) Serve European Customers?" Harvard Business School Case 808-099, December 2007. (Revised May 2009.)
- 03 Apr 2006
- Research & Ideas
The Competitive Advantage of Global Finance
In the process, he shows how organizations can best equip themselves to take advantage of potential sources of competitive advantage that arise in the global setting. In International Finance: A Casebook, Desai provides case studies on how large View Details
- 26 Apr 2010
- News
Pharma's Future Depends on These Three Trends
- August 2023 (Revised May 2024)
- Case
Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations
By: Satish Tadikonda and Amanda McEwen
The success or failure of Dicerna Pharmaceuticals (Dicerna) as an emerging pharmaceutical company would likely hinge on its lead drug candidate Nedosiran and the company’s ability to see it successfully through clinical development. Ralf Rosskamp, Chief Medical... View Details
Keywords: Business Strategy; Health Testing and Trials; Product Development; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry
Tadikonda, Satish, and Amanda McEwen. "Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations." Harvard Business School Case 824-018, August 2023. (Revised May 2024.)
- February 2017
- Supplement
JCDecaux, 2016: Global Leader ... Again
By: John R. Wells and Gabriel Ellsworth
In 2016, JCDecaux was number one in the world in outdoor advertising. This was a far cry from the situation in 2003; at that time, JCDecaux had been unseated by Clear Channel from the number-one spot that it had held for decades, and it was fighting for second place... View Details
Keywords: JCDecaux; Clear Channel Outdoor; OUTFRONT Media; Lamar Advertising Company; Jean-François Decaux; Jean-Charles Decaux; Outdoor Advertising; Street Furniture; Airports; Billboards; Bicycles; Digital Devices; Digital Marketing; Bidding; Advertising; Advertising Campaigns; Acquisition; Mergers and Acquisitions; Business Growth and Maturation; Business Model; Business Organization; Family Business; For-Profit Firms; Joint Ventures; Design; Price; Profit; Revenue; Geographic Location; Geographic Scope; Global Range; Globalization; Global Strategy; Globalized Firms and Management; Multinational Firms and Management; Globalized Markets and Industries; Government Legislation; Business History; Human Resources; Laws and Statutes; Business or Company Management; Goals and Objectives; Growth and Development Strategy; Growth Management; Marketing; Brands and Branding; Marketing Channels; Marketing Strategy; Product Marketing; Demand and Consumers; Supply and Industry; Operations; Distribution; Infrastructure; Logistics; Product; Product Design; Production; Organizational Structure; Property; Public Ownership; Renting or Rental; Problems and Challenges; Business and Community Relations; Business and Government Relations; Family and Family Relationships; Sales; Situation or Environment; Luxury; Strategy; Business Strategy; Commercialization; Competition; Competitive Advantage; Competitive Strategy; Consolidation; Corporate Strategy; Customization and Personalization; Expansion; Segmentation; Mobile Technology; Wireless Technology; Air Transportation; Bicycle Transportation; Rail Transportation; Transportation Networks; Advertising Industry; France; Paris
Wells, John R., and Gabriel Ellsworth. "JCDecaux, 2016: Global Leader ... Again." Harvard Business School Supplement 717-441, February 2017.
- October 2016 (Revised February 2017)
- Teaching Note
Alvogen
By: Daniel Isenberg, William R. Kerr and Alexis Brownell
Alvogen is an Icelandic pharmaceutical company that makes and sells generic drugs. Founder and CEO Robert Wessman is deciding whether to take on private equity investors willing to buy out all shareholders, merge with a large and publicly-traded US pharmaceutical... View Details
- 13 Nov 2012
- First Look
First Look: November 13
finds that academic commentary on the BSC often ignores its role in strategy execution. The paper discusses how the BSC can be used in public sector applications, as well as for companies that want to internalize environmental, social,... View Details
Keywords: Sean Silverthorne
- 27 Sep 2006
- Research & Ideas
Report From Egypt: Studying Global Influences
multinationals that move people across locations, expect frequent travel outside the country, and emphasize abundant training and Web-based process tools. Part of the mission of all three companies in Egypt... View Details
Keywords: by Sean Silverthorne